DSpace at KISTKIST Article2016

Full metadata record

DC Field Value Language
dc.contributor.authorLee, So Jin-
dc.contributor.authorKim, Min Ju-
dc.contributor.authorKwon, Ick Chan-
dc.contributor.authorRoberts, Thomas M.-
dc.date.accessioned2024-01-20T03:31:57Z-
dc.date.available2024-01-20T03:31:57Z-
dc.date.created2022-01-25-
dc.date.issued2016-09-
dc.identifier.issn0169-409X-
dc.identifier.urihttps://pubs.kist.re.kr/handle/201004/123701-
dc.description.abstractSmall interfering RNA (siRNA) has gained attention as a potential therapeutic reagent due to its ability to inhibit specific genes in many genetic diseases. For many years, studies of siRNA have progressively advanced toward novel treatment strategies against cancer. Cancer is caused by various mutations in hundreds of genes including both proto-oncogenes and tumor suppressor genes. In order to develop siRNAs as therapeutic agents for cancer treatment, delivery strategies for siRNA must be carefully designed and potential gene targets carefully selected for optimal anti-cancer effects. In this review, various modifications and delivery strategies for siRNA delivery are discussed. In addition, we present current thinking on target gene selection in major tumor types. (C) 2016 Elsevier B.V. All rights reserved.-
dc.languageEnglish-
dc.publisherELSEVIER-
dc.titleDelivery strategies and potential targets for siRNA in major cancer types-
dc.typeArticle-
dc.identifier.doi10.1016/j.addr.2016.05.010-
dc.description.journalClass1-
dc.identifier.bibliographicCitationADVANCED DRUG DELIVERY REVIEWS, v.104, pp.2 - 15-
dc.citation.titleADVANCED DRUG DELIVERY REVIEWS-
dc.citation.volume104-
dc.citation.startPage2-
dc.citation.endPage15-
dc.description.isOpenAccessN-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.identifier.wosid000381239300002-
dc.identifier.scopusid2-s2.0-84973527084-
dc.relation.journalWebOfScienceCategoryPharmacology & Pharmacy-
dc.relation.journalResearchAreaPharmacology & Pharmacy-
dc.type.docTypeReview-
dc.subject.keywordPlusSMALL INTERFERING RNA-
dc.subject.keywordPlusIN-VIVO DELIVERY-
dc.subject.keywordPlusNANOPARTICLE-BASED DELIVERY-
dc.subject.keywordPlusPROTEIN-KINASE CK2-
dc.subject.keywordPlusBREAST-CANCER-
dc.subject.keywordPlusSYSTEMIC DELIVERY-
dc.subject.keywordPlusOVARIAN-CANCER-
dc.subject.keywordPlusHEPATOCELLULAR-CARCINOMA-
dc.subject.keywordPlusPOLYMERIZED SIRNA-
dc.subject.keywordPlusTUMOR-GROWTH-
dc.subject.keywordAuthorSmall interfering RNA (siRNA)-
dc.subject.keywordAuthorDelivery strategy of siRNAs-
dc.subject.keywordAuthorCancer-
dc.subject.keywordAuthorsiRNA therapeutics-
dc.subject.keywordAuthorGene target-
Appears in Collections:
KIST Article > 2016
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML
Show Simple Item Record

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE